In vivo supramolecular templating enhances the activity of multivalent ligands: A potential therapeutic against the Escherichia coli O157 AB5 toxins

被引:65
作者
Kitov, Pavel I. [1 ]
Mulvey, George L. [2 ]
Griener, Thomas P. [2 ]
Lipinski, Tomasz [1 ]
Solomon, Dmitry [1 ]
Paszkiewicz, Eugenia [1 ]
Jacobson, Jared M. [1 ]
Sadowska, Joanna M. [1 ]
Suzuki, Missao [3 ]
Yamamura, Ken-ichi [3 ]
Armstrong, Glen D. [2 ]
Bundle, David R. [1 ]
机构
[1] Univ Alberta, Dept Chem, Alberta Ingenu Ctr Carbohydrate Sci, Edmonton, AB T6G 2G2, Canada
[2] Univ Calgary, Dept Microbiol & Infect Dis, Alberta Ingenu Ctr Carbohydrate Sci, Calgary, AB T2N 4N1, Canada
[3] Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Kumamoto 8620976, Japan
基金
加拿大自然科学与工程研究理事会;
关键词
heterobifunctional ligand; multivalency; Shiga toxin;
D O I
10.1073/pnas.0804919105
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
We demonstrate that interactions between multimeric receptors and multivalent ligands are dramatically enhanced by recruiting a complementary templating receptor such as an endogenous multimeric protein but only when individual ligands are attached to a polymer as preorganized, covalent, heterobifunctional pairs. This effect cannot be replicated by a multivalent ligand if the same recognition elements are independently arrayed on the scaffold. Application of this principle offers an approach to create high-avidity inhibitors for multimeric receptors. Judicious selection of the ligand that engages the templating protein allows appropriate effector function to be incorporated in the polymeric construct, thereby providing an opportunity for therapeutic applications. The power of this approach is exemplified by the design of exceptionally potent Escherichia coli Shiga toxin antagonists that protect transgenic mice that constitutively express a human pentraxin, serum amyloid P component.
引用
收藏
页码:16837 / 16842
页数:6
相关论文
共 34 条
[1]   Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo:: Therapeutic implications for hemolytic-uremic syndrome [J].
Armstrong, GD ;
Mulvey, GL ;
Marcato, P ;
Griener, TP ;
Kahan, MC ;
Tennent, GA ;
Sabin, CA ;
Chart, H ;
Pepys, MB .
JOURNAL OF INFECTIOUS DISEASES, 2006, 193 (08) :1120-1124
[2]   A PHASE-I STUDY OF CHEMICALLY SYNTHESIZED VEROTOXIN (SHIGA-LIKE TOXIN) PK-TRISACCHARIDE RECEPTORS ATTACHED TO CHROMOSORB FOR PREVENTING HEMOLYTIC-UREMIC SYNDROME [J].
ARMSTRONG, GD ;
ROWE, PC ;
GOODYER, P ;
ORRBINE, E ;
KLASSEN, TP ;
WELLS, G ;
MACKENZIE, A ;
LIOR, H ;
BLANCHARD, C ;
AUCLAIR, F ;
THOMPSON, B ;
RAFTER, DJ ;
MCLAINE, PN .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (04) :1042-1045
[3]   Multivalency and cooperativity in supramolecular chemistry [J].
Badjic, JD ;
Nelson, A ;
Cantrill, SJ ;
Turnbull, WB ;
Stoddart, JF .
ACCOUNTS OF CHEMICAL RESEARCH, 2005, 38 (09) :723-732
[4]   The dawning era of polymer therapeutics [J].
Duncan, R .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (05) :347-360
[5]   Influencing receptor-ligand binding mechanisms with multivalent ligand architecture [J].
Gestwicki, JE ;
Cairo, CW ;
Strong, LE ;
Oetjen, KA ;
Kiessling, LL .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (50) :14922-14933
[6]   Ligand-assisted aggregation of proteins - Dimerization of serum amyloid p component by bivalent ligands [J].
Ho, JGS ;
Kitov, PI ;
Paszkiewicz, E ;
Sadowska, J ;
Bundle, DR ;
Ng, KKS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (36) :31999-32008
[7]   Synthesis of fullerene glycoconjugates via a copper-catalyzed Huisgen cycloaddition reaction [J].
Isobe, Hiroyuki ;
Cho, Kaimei ;
Solin, Niclas ;
Werz, Daniel B. ;
Seeberger, Peter H. ;
Nakamura, Eiichi .
ORGANIC LETTERS, 2007, 9 (22) :4611-4614
[8]   Differentiation between structurally homologous Shiga 1 and Shiga 2 toxins by using synthetic glycoconjugates [J].
Kale, Ramesh R. ;
McGannon, Colleen M. ;
Fuller-Schaefer, Cynthia ;
Hatch, Duane M. ;
Flagler, Michael J. ;
Gamage, Shantini D. ;
Weiss, Alison A. ;
Iyer, Suri S. .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2008, 47 (07) :1265-1268
[9]   Serum amyloid P component is the shiga toxin 2-neutralizing factor in human blood [J].
Kimura, T ;
Tani, S ;
Matsumoto, Y ;
Takeda, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (45) :41576-41579
[10]   An entropically efficient supramolecular inhibition strategy for Shiga toxins [J].
Kitov, Pavel I. ;
Lipinski, Tomasz ;
Paszkiewicz, Eugenia ;
Solomon, Dmitry ;
Sadowska, Joanna M. ;
Grant, Gordon A. ;
Mulvey, George L. ;
Kitova, Elena N. ;
Klassen, John S. ;
Armstrong, Glen D. ;
Bundle, David R. .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2008, 47 (04) :672-676